APA

Richardson P. G., Hofmeister C. C., Raje N. S., Siegel D. S., Lonial S., Laubach J., Efebera Y. A., Vesole D. H., Nooka A. K., Rosenblatt J., Doss D., Zaki M. H., Bensmaine A., Herring J., Li Y., Watkins L., Chen M. S. & Anderson K. C. (102018). Correction: Pomalidomide, bortezomib, and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma. : Leukemia.

Chicago

Richardson P G, Hofmeister C C, Raje N S, Siegel D S, Lonial S, Laubach J, Efebera Y A, Vesole D H, Nooka A K, Rosenblatt J, Doss D, Zaki M H, Bensmaine A, Herring J, Li Y, Watkins L, Chen M S and Anderson K C. 102018. Correction: Pomalidomide, bortezomib, and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma. : Leukemia.

Harvard

Richardson P. G., Hofmeister C. C., Raje N. S., Siegel D. S., Lonial S., Laubach J., Efebera Y. A., Vesole D. H., Nooka A. K., Rosenblatt J., Doss D., Zaki M. H., Bensmaine A., Herring J., Li Y., Watkins L., Chen M. S. and Anderson K. C. (102018). Correction: Pomalidomide, bortezomib, and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma. : Leukemia.

MLA

Richardson P G, Hofmeister C C, Raje N S, Siegel D S, Lonial S, Laubach J, Efebera Y A, Vesole D H, Nooka A K, Rosenblatt J, Doss D, Zaki M H, Bensmaine A, Herring J, Li Y, Watkins L, Chen M S and Anderson K C. Correction: Pomalidomide, bortezomib, and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma. : Leukemia. 102018.